A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Akums combines two potent diabetes medicines for enhanced treatment efficacy: Our Bureau, Bengaluru Tuesday, February 4, 2025, 15:30 Hrs [IST] Akums Drugs and Pharmaceuticals, a l ...

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.